A trilogy of primary prevention statin trials. Panel discussion.
暂无分享,去创建一个
A. Gotto | Y. Matsuzawa | F. Sacks | T. Kita | J. Sasaki | S. Oikawa | J. Shepherd | H. Nakamura
[1] M. Sabatine,et al. Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations: CARE and WOSCOPS , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[2] S. Yamashita,et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. , 2000, Atherosclerosis.
[3] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[4] S. Yamashita,et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[5] Caroline A. Lee,et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.
[6] Y. Ouchi,et al. Serum lipid survey and its recent trend in the general Japanese population in 2000. , 2005, Journal of atherosclerosis and thrombosis.
[7] O. Wiklund,et al. Cholesterol reduction and clinical benefit. Are there limits to our expectations? , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[8] Yasuo Ohashi,et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.
[9] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[10] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[11] J W Jukema,et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.
[12] R. Westendorp,et al. TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia , 2005, European Journal of Human Genetics.